Russell Greig, once president of GlaxoSmithKline subsidiary SR One, has taken the chairman position at drug developer BiomX, nine years after leaving the unit.

JMDC, Gene Techno Science, Astellas Venture Management and Nissay Capital have contributed to a $25.8m round for Keio University's heart failure treatment developer.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

FerGene has been spun off by Ferring Pharmaceuticals to bring a gene therapy for bladder cancer to market, and Ferring itself is supplying $170m of the cash.

Kairos Ventures, a venture capital firm with ties to multiple academic institutions, hopes to raise $250m for its third main fund.

JMDC, Gene Techno Science, Astellas Venture Management and Nissay Capital contributed to a $25.8m round for the heart failure treatment developer.

University of Arizona's tech transfer office generated 11 spinouts during the past financial year sealed 96 licence and option agreements.

Brii Biosciences was among the participants in a series A round for infectious disease drug developer AN2 and has secured Chinese commercialisation rights for the startup's lead asset.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Novartis, Bayer, Evotec, Merck Group and Alexandria Real Estate Equities all invested in Longwood Fund-founded cancer immunotherapy startup Immunitas Therapeutics.